Indeed, treating HNSCC cells (FaDu and SCC-61) with a combination of GLUT1 inhibitors (WZB117, 20 μmol/L, or BAY-876, 100 nmol/L) and vitamin C (0.25 mmol/L) dramatically reduced cellular proliferation compared with either monotherapy (Fig. 5A and B). Here, SLC2A1 is linked to head and neck squamous cell carcinoma.